市場調査レポート

商品コード

1453897

統合失調感情障害の2030年までの市場予測：タイプ別、原因別、用途別、エンドユーザー別、地域別の世界分析

Schizoaffective Disorders Market Forecasts to 2030 - Global Analysis By Type (Medication and Psychotherapy), Cause, Application, End User, and By Geography

出版日: 2024年03月03日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 602,912円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 762,720円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 922,528円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,089,600円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.28円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の統合失調感情障害市場は2023年に76億米ドルを占め、予測期間中にCAGR 4.9％で成長し、2030年には107億米ドルに達すると予測されています。

統合失調感情障害は、幻覚や妄想などの統合失調症の症状と、うつ病や躁病などの気分障害が組み合わさった慢性的な精神疾患です。統合失調感情障害の患者は通常、著しい気分障害とともに、何が現実で何が現実でないかの区別が困難になる精神病の時期を経験します。治療には通常、抗精神病薬、気分安定薬、心理療法を組み合わせて症状を管理し、機能を改善します。

WHOによると、2018年には世界で9億7,000万人、つまり8人に1人が不安障害や抑うつ障害を含む精神疾患を患っていました。現在、世界中で成人の約19.86％が精神疾患を経験しています。

認識と診断の向上

市場における認知度の向上と診断の強化は、タイムリーな介入と患者の転帰の改善にとって極めて重要です。対象を絞った教育キャンペーンを通じて、医療専門家は微妙な症状をよりよく認識できるようになり、早期発見と適切な治療戦略が促進されます。さらに、地域社会へのアウトリーチプログラムは、個人や家族が助けを求める力を与え、スティグマを軽減し、罹患者を支援する環境を醸成することができます。

精神病にまつわる偏見

認知の進歩にもかかわらず、誤解は根強く、受け入れや治療へのアクセスを妨げています。この障害を持つ人は、しばしば社会的排斥や差別に直面し、社会への統合や雇用の機会を妨げられています。このスティグマは精神的苦痛を悪化させるだけでなく、助けを求めることを躊躇させ、孤立と未治療の症状のサイクルを永続させる。したがって、これが市場の成長を阻害する大きな要因となっています。

個別化医療への注目

個別化医療は、この疾患の治療において大きな可能性を秘めています。遺伝的、神経生物学的、環境学的要因を統合したオーダーメイドのアプローチは、従来の画一的な治療法からの大きな転換をもたらします。精密医療は、臨床医が個々の患者の特徴に基づいて治療法を選択し、有効性を高め、副作用を最小限に抑えることを可能にします。したがって、これらが市場の成長を後押しする要因となっています。

高い治療費

統合失調感情障害の治療には大きな経済的負担が伴い、その費用はしばしば法外な水準に達します。これには薬物療法、治療、入院、継続的な精神科治療に関する費用が含まれます。さらに、生産性の低下や社会的支援の喪失といった間接的なコストが、個人とその家族の経済的負担をさらにエスカレートさせる。そのため、統合失調感情障害の管理コストが高いことが、市場の成長を妨げる要因となっています。

COVID-19の影響：

COVID-19の流行は市場に大きな影響を与え、治療へのアクセスや患者のケアに混乱を引き起こしました。封鎖措置、医療施設の能力低下、COVID-19管理へのリソースの優先順位付けが、統合失調感情障害患者の診断、治療開始、治療調整の遅れにつながった。遠隔医療は遠隔診察のための重要なツールとして登場したが、デジタルアクセスやケアの質における格差は依然として残っています。

予測期間中、心理療法セグメントが最大となる見込み

予測期間中、心理療法セグメントが最大となる見込み。心理療法は統合失調感情障害の管理において重要な役割を果たし、薬物療法と並んで包括的なアプローチを提供します。認知行動療法（CBT）、支持療法、家族療法は一般的に利用されている方法です。これらの療法は、対処戦略を強化し、社会機能を改善し、服薬アドヒアランスを促進することを目的としています。

予測期間中、病院セグメントのCAGRが最も高くなると予測される

予測期間中にCAGRが最も高くなると予想されるのは病院セグメントです。統合失調感情障害市場に対応する病院は、この複雑な精神状態を経験する人々に合わせた専門的なケアを提供しています。これらの施設は、統合失調感情障害患者特有のニーズに対応することを目的として、診断、投薬管理、治療、支援プログラムなどの包括的なサービスを提供しています。

最大のシェアを占める地域

北米は、認知度の向上、診断技術の改善、治療法の進歩により、予測期間中最大の市場シェアを占めると予測されます。製薬企業は研究開発に投資し、精神病症状と感情症状の両方に対応する新しい治療法を導入し、患者の転帰を向上させています。さらに、政府の支援策や医療改革が市場拡大をさらに後押ししています。

CAGRが最も高い地域：

予測期間中、アジア太平洋が最も高いCAGRを維持すると予測されます。同地域では、メンタルヘルスサービスの利用可能性とアクセシビリティが国によって大きく異なります。メンタルヘルスサービスへの資金提供や新たな治療法の研究開発支援など、メンタル医療に関する政府の政策と政策は、同地域の統合失調感情障害治療市場に大きな影響を与える可能性があります。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

企業プロファイル
- 追加市場参入企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

イントロダクション
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東・アフリカ

第10章主要発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Abbott Pharmaceuticals
AstraZeneca PLC
Bright Quest
Bristol Myers Squibb
Cascade Behavioural Health Hospital
Ciba Pharmaceuticals
Cleveland Clinic
Covington Behavioural Health Hospital
Delta Medical Center
Elan Pharmaceuticals
Eli Lilly and Company
Janssen cilag Pvt. Ltd.
Johnson and Johnson
Merz Pharma GmbH & Co.
Pfizer

図表

List of Tables

Table 1 Global Schizoaffective Disorders Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 3 Global Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
Table 4 Global Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
Table 5 Global Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
Table 6 Global Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
Table 7 Global Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
Table 8 Global Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
Table 9 Global Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
Table 10 Global Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
Table 11 Global Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
Table 12 Global Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
Table 13 Global Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
Table 14 Global Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
Table 15 Global Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
Table 16 Global Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
Table 17 Global Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 18 Global Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
Table 19 Global Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
Table 20 Global Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 21 Global Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
Table 22 Global Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
Table 23 Global Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
Table 24 North America Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
Table 25 North America Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 26 North America Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
Table 27 North America Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
Table 28 North America Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
Table 29 North America Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
Table 30 North America Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
Table 31 North America Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
Table 32 North America Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
Table 33 North America Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
Table 34 North America Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
Table 35 North America Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
Table 36 North America Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
Table 37 North America Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
Table 38 North America Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
Table 39 North America Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
Table 40 North America Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 41 North America Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
Table 42 North America Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
Table 43 North America Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 44 North America Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
Table 45 North America Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
Table 46 North America Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
Table 47 Europe Stain-Resistant Fabric Market Outlook, By Country (2021-2030) ($MN)
Table 48 Europe Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 49 Europe Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
Table 50 Europe Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
Table 51 Europe Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
Table 52 Europe Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
Table 53 Europe Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
Table 54 Europe Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
Table 55 Europe Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
Table 56 Europe Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
Table 57 Europe Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
Table 58 Europe Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
Table 59 Europe Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
Table 60 Europe Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
Table 61 Europe Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
Table 62 Europe Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
Table 63 Europe Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 64 Europe Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
Table 65 Europe Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
Table 66 Europe Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 67 Europe Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
Table 68 Europe Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
Table 69 Europe Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
Table 70 Asia Pacific Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
Table 71 Asia Pacific Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 72 Asia Pacific Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
Table 73 Asia Pacific Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
Table 74 Asia Pacific Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
Table 75 Asia Pacific Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
Table 76 Asia Pacific Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
Table 77 Asia Pacific Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
Table 78 Asia Pacific Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
Table 79 Asia Pacific Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
Table 80 Asia Pacific Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
Table 81 Asia Pacific Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
Table 82 Asia Pacific Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
Table 83 Asia Pacific Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
Table 84 Asia Pacific Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
Table 85 Asia Pacific Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
Table 86 Asia Pacific Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 87 Asia Pacific Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
Table 88 Asia Pacific Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
Table 89 Asia Pacific Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 90 Asia Pacific Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
Table 91 Asia Pacific Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
Table 92 Asia Pacific Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
Table 93 South America Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
Table 94 South America Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 95 South America Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
Table 96 South America Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
Table 97 South America Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
Table 98 South America Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
Table 99 South America Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
Table 100 South America Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
Table 101 South America Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
Table 102 South America Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
Table 103 South America Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
Table 104 South America Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
Table 105 South America Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
Table 106 South America Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
Table 107 South America Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
Table 108 South America Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
Table 109 South America Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 110 South America Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
Table 111 South America Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
Table 112 South America Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 113 South America Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
Table 114 South America Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
Table 115 South America Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
Table 116 Middle East & Africa Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
Table 117 Middle East & Africa Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 118 Middle East & Africa Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
Table 119 Middle East & Africa Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
Table 120 Middle East & Africa Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
Table 121 Middle East & Africa Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
Table 122 Middle East & Africa Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
Table 123 Middle East & Africa Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
Table 124 Middle East & Africa Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
Table 125 Middle East & Africa Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
Table 126 Middle East & Africa Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
Table 127 Middle East & Africa Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
Table 128 Middle East & Africa Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
Table 129 Middle East & Africa Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
Table 130 Middle East & Africa Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
Table 131 Middle East & Africa Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
Table 132 Middle East & Africa Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 133 Middle East & Africa Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
Table 134 Middle East & Africa Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
Table 135 Middle East & Africa Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 136 Middle East & Africa Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
Table 137 Middle East & Africa Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
Table 138 Middle East & Africa Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC25449

According to Stratistics MRC, the Global Schizoaffective Disorders Market is accounted for $7.6 billion in 2023 and is expected to reach $10.7 billion by 2030 growing at a CAGR of 4.9% during the forecast period. Schizoaffective disorder is a chronic mental health condition characterized by a combination of symptoms of schizophrenia, such as hallucinations or delusions, and mood disorders, such as depression or mania. Individuals with schizoaffective disorder typically experience periods of psychosis, during which they may have difficulty distinguishing between what is real and what is not, along with significant mood disturbances. Treatment usually involves a combination of antipsychotic medications, mood stabilizers, and psychotherapy to manage symptoms and improve functioning.

According to WHO, in 2018, 970 million individuals worldwide, or 1 in every eight persons, had a mental illness, including anxiety and depressive disorders. Now, around 19.86% of adults are experiencing a mental illness worldwide.

Market Dynamics:

Driver:

Increasing awareness and diagnosis

Raising awareness and enhancing diagnosis in the market is crucial for timely intervention and improved patient outcomes. Through targeted educational campaigns, healthcare professionals can better recognize the nuanced symptoms, facilitating early identification and appropriate treatment strategies. Additionally, community outreach programs can empower individuals and families to seek help, reducing stigma and fostering a supportive environment for those affected.

Restraint:

Stigma associated with mental illness

Despite strides in awareness, misconceptions persist, hindering acceptance and access to treatment. Individuals with this disorder often face social ostracization and discrimination, impeding their integration into society and employment opportunities. This stigma not only exacerbates their psychological distress but also deters them from seeking help, perpetuating a cycle of isolation and untreated symptoms. Thus, this is the major factor impeding the growth of the market.

Opportunity:

Focus on personalized medicine

Personalized medicine holds immense promise in the treatment landscape of this disorder. Tailored approaches, integrating genetic, neurobiological, and environmental factors, offer a profound shift from traditional one-size-fits-all treatments. Precision medicine enables clinicians to select therapies based on individual patient characteristics, enhancing efficacy and minimizing adverse effects. Hence, these are the factors propelling the growth of the market.

Threat:

High cost of treatment

The treatment of schizoaffective disorder presents significant financial burdens, with costs often reaching exorbitant levels. This encompasses expenses related to medication, therapy, hospitalizations, and ongoing psychiatric care. Additionally, indirect costs such as lost productivity and social support further escalate the financial strain on individuals and their families. Therefore, the high cost of managing schizoaffective disorder is the factor hampering the growth of the market.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the market, causing disruptions in treatment access and patient care. Lockdown measures, reduced healthcare facility capacities, and prioritization of resources towards COVID-19 management led to delays in diagnosis, treatment initiation, and therapy adjustments for schizoaffective disorder patients. Telehealth emerged as a vital tool for remote consultations, but disparities in digital access and quality of care persisted.

The psychotherapy segment is expected to be the largest during the forecast period

The psychotherapy segment is expected to be the largest during the forecast period. Psychotherapy plays a crucial role in the management of Schizoaffective Disorder, offering a comprehensive approach alongside medication. Cognitive-behavioral therapy (CBT), supportive therapy, and family therapy are commonly utilized modalities. They aim to enhance coping strategies, improve social functioning, and facilitate medication adherence.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. Hospitals catering to the Schizoaffective Disorders market offer specialized care tailored to individuals experiencing this complex mental health condition. These facilities provide comprehensive services, including diagnosis, medication management, therapy, and support programs, aimed at addressing the unique needs of patients with schizoaffective disorders.

Region with largest share:

North America is projected to hold the largest market share during the forecast period driven by increasing awareness, improved diagnostic techniques, and advancements in treatment options. Pharmaceutical companies are investing in research and development to introduce novel therapies addressing both psychotic and affective symptoms, enhancing patient outcomes. Additionally, supportive government initiatives and healthcare reforms further propel market expansion.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The availability and accessibility of mental health services vary widely across countries in the region. Government policies and regulations regarding mental health care, including funding for mental health services and support for research and development of new treatment options, can significantly impact the market for schizoaffective disorder treatment in the region.

Key players in the market

Some of the key players in Schizoaffective Disorders market include Abbott Pharmaceuticals, AstraZeneca PLC, Bright Quest, Bristol Myers Squibb, Cascade Behavioural Health Hospital, Ciba Pharmaceuticals, Cleveland Clinic, Covington Behavioural Health Hospital, Delta Medical Center, Elan Pharmaceuticals, Eli Lilly and Company, Janssen cilag Pvt. Ltd., Johnson and Johnson, Merz Pharma GmbH & Co. And Pfizer.

Key Developments:

In January 2024, Abbott announced that the U.S. Food and Drug Administration (FDA) has approved expanded MRI labeling for its dorsal root ganglion (DRG) stimulation therapy, the Proclaim(TM) DRG neurostimulation system, which allows patients to receive full-body MRI scans while implanted with the device.

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Types Covered:

Medication
Psychotherapy

Causes Covered:

Genetic Factors
Environmental Factors
Chemical Factors

Applications Covered:

Devices
Drugs
Diagnostics
Other Applications

End Users Covered:

Online Pharmacy
Hospitals
Retail pharmacy
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Schizoaffective Disorders Market, By Type

5.1 Introduction
5.2 Medication
- 5.2.1 Mood stabilizers
- 5.2.2 Antipsychotics
- 5.2.3 Antidepressants
5.3 Psychotherapy
- 5.3.1 Individual Therapy
- 5.3.2 Group Therapy

6 Global Schizoaffective Disorders Market, By Cause

6.1 Introduction
6.2 Genetic Factors
6.3 Environmental Factors
6.4 Chemical Factors

7 Global Schizoaffective Disorders Market, By Application

7.1 Introduction
7.2 Devices
7.3 Drugs
7.4 Diagnostics
7.5 Other Applications

8 Global Schizoaffective Disorders Market, By End User

8.1 Introduction
8.2 Online Pharmacy
8.3 Hospitals
8.4 Retail pharmacy
8.5 Other End Users

9 Global Schizoaffective Disorders Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Abbott Pharmaceuticals
11.2 AstraZeneca PLC
11.3 Bright Quest
11.4 Bristol Myers Squibb
11.5 Cascade Behavioural Health Hospital
11.6 Ciba Pharmaceuticals
11.7 Cleveland Clinic
11.8 Covington Behavioural Health Hospital
11.9 Delta Medical Center
11.10 Elan Pharmaceuticals
11.11 Eli Lilly and Company
11.12 Janssen cilag Pvt. Ltd.
11.13 Johnson and Johnson
11.14 Merz Pharma GmbH & Co.
11.15 Pfizer

統合失調感情障害の2030年までの市場予測：タイプ別、原因別、用途別、エンドユーザー別、地域別の世界分析

Schizoaffective Disorders Market Forecasts to 2030 - Global Analysis By Type (Medication and Psychotherapy), Cause, Application, End User, and By Geography

COVID-19の影響：

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の統合失調感情障害市場：タイプ別

第6章 世界の統合失調感情障害市場：原因別

第7章 世界の統合失調症感情障害市場：用途別

第8章 世界の統合失調症感情障害市場：エンドユーザー別

第9章 世界の統合失調症感情障害市場：地域別

第10章 主要発展

第11章 企業プロファイル